newsfilter
← Latest News
GlobeNewswire·

RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales

-- Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for full year 2022 -- --